EST
OVID icon

EA Series Trust’s Ovid Therapeutics OVID Stock Holding History

EA Series Trust’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$325K Buy
+98,952
New +$336K 0.01% 936

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EA Series Trust's OVID Position: Q2 2023 in Review

EA Series Trust opened a new position in Ovid Therapeutics (OVID) in Q2 2023: 98,952 shares worth $325K. The stake represents 0.01% of the portfolio and ranks #936 among its holdings.

69 funds tracked by Wall St. Rank hold OVID as of Q2 2023.

  • EA Series Trust held 98,952 shares of Ovid Therapeutics worth $325K as of Q2 2023.
  • Ovid Therapeutics was a new EA Series Trust position in Q2 2023.
  • Ovid Therapeutics made up 0.01% of EA Series Trust's portfolio in Q2 2023, its #936 holding.
  • 69 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.